Chronic Bronchitis
10,000,000+
People living with Chronic Bronchitis with Moderate/Severe Mucus Symptoms in the US
Limited Treatment Options
Lack efficacy, especially for mucus and cough
ARINA-1 is poised to be a first-line therapy for improving airway hygiene by clearing mucus and decreasing inflammation in Chronic Bronchitis (CB).
CB is most commonly caused by chronic bronchial inflammation that leads to excess mucus in the airway and scarring. CB is characterized by excess mucus, chronic cough, and progressive lung damage that can lead to decreased pulmonary function. CB primarily impacts people over the age of 40 and significantly impairs quality of life. Current treatments vary in efficacy and have a limited impact on quality of life.
Current Status
Phase 2 Clinical Trial
US Only Trial
Study Information Coming soon
Duration:
24 Weeks - Randomized, Double-Blind, Placebo-Controlled Trial
Tial number:
Coming Soon
Patient Enrollment Status
Pending; Projected Start Q4 2026
Interested in being a Trial Site?
Other Target Indications for ARINA·1
